Actively Recruiting
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
Led by Ayal A. Aizer, MD · Updated on 2026-03-19
60
Participants Needed
1
Research Sites
191 weeks
Total Duration
On this page
Sponsors
A
Ayal A. Aizer, MD
Lead Sponsor
V
Varian, a Siemens Healthineers Company
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study is to evaluate the feasibility and effectiveness of same-day radiation planning and treatment. The study will shorten the time interval between radiation planning (radiation mapping) and radiation treatment. The intent of this shorter time interval is to increase the likelihood that the brain metastases being treated remain fully within the high-dose radiation fields. Participants will be randomized to receive brain-directed stereotactic radiation with a 1mm margin or 0mm margin, have their simulation/radiation planning imaging on the same day that brain-directed stereotactic radiation is delivered, and have repeat simulation/radiation planning scans during the course of treatment if more than 2-3 days have elapsed since the most recent scans.
CONDITIONS
Official Title
Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must have a biopsy confirmed solid cancer with at least one brain metastasis that shows growth of 1.0mm per week or more on recent MRIs, or is close to edema, a recent surgical cavity, or another source of displacement
- Age at least 18 years
- Karnofsky performance status of at least 60
- Estimated survival of at least 3 to 6 months according to the enrolling clinician
- Ability and willingness to provide written informed consent by paper or approved electronic methods
You will not qualify if you...
- Inability to tolerate a brain MRI
- Inability to receive gadolinium contrast
- End stage renal disease
- Widespread definitive leptomeningeal disease
- Pregnant women or breastfeeding women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Brigham and Women's Hospital / Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Actively Recruiting
Research Team
A
Ayal A Aizer, MD, MHS
CONTACT
I
Ivy B Ricca, BA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here